In the same year, Li et al. reported the results of a phase II study evaluating systemic monotherapy with durvalumab, a human IgG1 monoclonal antibody targeting PD-L1, in 17 patients with BCG-unresponsive CIS. This evidence concerns the gene CD274 and in situ carcinoma.